| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Fumitaka Shimizu, Takashi Kand. [Disruption of blood-brain barrier in multiple sclerosis and neuromyelitis optica]. Nihon rinsho. Japanese journal of clinical medicine. vol 72. issue 11. 2015-01-08. PMID:25518376. |
pathological destruction of the blood-brain barrier(bbb) has been considered to be the initial key step of disease process in multiple sclerosis (ms) and neuromyelitis optica (nmo). |
2015-01-08 |
2023-08-13 |
Not clear |
| Ichiro Nakashim. [Diagnostic criteria and differential diagnosis of neuromyelitis optica]. Nihon rinsho. Japanese journal of clinical medicine. vol 72. issue 11. 2015-01-08. PMID:25518378. |
neuromyelitis optica (nmo) is an autoimmune central nervous system disease associated with anti-aquaporin 4 (aqp4) antibody. |
2015-01-08 |
2023-08-13 |
Not clear |
| Izumi Kawachi, Masatoyo Nishizaw. [Characteristic features of radiological findings in multiple sclerosis and neuromyelitis optica]. Nihon rinsho. Japanese journal of clinical medicine. vol 72. issue 11. 2015-01-08. PMID:25518380. |
multiple sclerosis (ms) and neuromyelitis optica (nmo) are the two main autoimmune and inflammatory diseases of the central nervous system (cns), and conventional magnetic resonance imaging (mri) is a currently-established tool in the diagnosis of these two diseases. |
2015-01-08 |
2023-08-13 |
Not clear |
| Takashi Ohash. [Short-term high-dose intravenous methylprednisolone therapy]. Nihon rinsho. Japanese journal of clinical medicine. vol 72. issue 11. 2015-01-08. PMID:25518383. |
ivmp is also applied in the acute phase of neuromyelitis optica (nmo), with considerable benefit, although some patients are refractory to ivmp, and the early use of plasmapheresis should be considered in these patients. |
2015-01-08 |
2023-08-13 |
Not clear |
| Hidenori Matsu. [Plasmapheresis in acute phase of multiple sclerosis and neuromyelitis optica]. Nihon rinsho. Japanese journal of clinical medicine. vol 72. issue 11. 2015-01-08. PMID:25518384. |
in acute phase of multiple sclerosis (ms) and neuromyelitis optica (nmo), plasmapheresis (pp) should be considered as the 2nd choice treatment when corticosteroid pulse therapy results in unsuccessful. |
2015-01-08 |
2023-08-13 |
Not clear |
| Kyoichi Nomur. [Prevention of relapse of neuromyelitis optica (NMO)]. Nihon rinsho. Japanese journal of clinical medicine. vol 72. issue 11. 2015-01-08. PMID:25518388. |
[prevention of relapse of neuromyelitis optica (nmo)]. |
2015-01-08 |
2023-08-13 |
Not clear |
| Toshiyuki Fukazawa, Fuminori Okazaki, Motoki Sawai, Kazuko Nishiyam. [Home hospice care, working support and rehabilitation for MS/NMO]. Nihon rinsho. Japanese journal of clinical medicine. vol 72. issue 11. 2015-01-08. PMID:25518391. |
there are a huge amount of physical, mental and financial handicaps to patients with multiple sclerosis (ms) or neuromyelitis optica (nmo) and their family members, although treatment strategies have remarkably progressed recently. |
2015-01-08 |
2023-08-13 |
Not clear |
| Yuko Shimiz. [How to manage medical treatment during pregnancy and childbirth]. Nihon rinsho. Japanese journal of clinical medicine. vol 72. issue 11. 2015-01-08. PMID:25518392. |
further studies are required to determine the potential risks associated with preconception and in utero disease-modifying-drug exposure in patients with ms. neuromyelitis optica (nmo), recent larger scale studies consistently showed that relapse rate in nmo was significantly higher during the first 3 months postpartum as compared with before or during pregnancy. |
2015-01-08 |
2023-08-13 |
rat |
| Keiko Tanaka, Masami Tanak. [Pathogenesis of autoantibodies in demyelinating disorders of the central nervous system]. Nihon rinsho. Japanese journal of clinical medicine. vol 72. issue 11. 2015-01-08. PMID:25518394. |
among them, anti-aquaporin 4(aqp4) antibody in neuromyelitis optica (nmo) is a reliable marker for the diagnosis of nmo and the antibody is thought to be closely related to its pathogenesis. |
2015-01-08 |
2023-08-13 |
Not clear |
| W Oliver Tobin, Brian G Weinshenker, Claudia F Lucchinett. Longitudinally extensive transverse myelitis. Current opinion in neurology. vol 27. issue 3. 2014-12-31. PMID:24792338. |
longitudinally extensive transverse myelitis (letm) is a frequently devastating clinical syndrome which has come into focus for its association with neuromyelitis optica (nmo). |
2014-12-31 |
2023-08-13 |
Not clear |
| Francesco Pisani, Maria Grazia Mola, Laura Simone, Stefania Rosito, Domenico Alberga, Giuseppe Felice Mangiatordi, Gianluca Lattanzi, Orazio Nicolotti, Antonio Frigeri, Maria Svelto, Grazia Paola Nicchi. Identification of a point mutation impairing the binding between aquaporin-4 and neuromyelitis optica autoantibodies. The Journal of biological chemistry. vol 289. issue 44. 2014-12-31. PMID:25239624. |
neuromyelitis optica (nmo) is characterized by the presence of pathogenic autoantibodies (nmo-iggs) against supra-molecular assemblies of aquaporin-4 (aqp4), known as orthogonal array of particles (oaps). |
2014-12-31 |
2023-08-13 |
Not clear |
| Shanthi Viswanathan, Masita Arip, Norhazlin Mustafa, Jasbir S Dhaliwal, Norzainie Rose, Sobri Muda, Santhi Datuk Puvanarajah, Mohammad Hanip Rafia, Mark Cheong Wing Loon. The frequency of anti-aquaporin-4 Ig g antibody in neuromyelitis optica and its spectrum disorders at a single tertiary referral center in malaysia. Multiple sclerosis international. vol 2014. 2014-12-30. PMID:25548676. |
to evaluate the frequency of anti-aquaporin-4 ig g antibody (anti-aqp4 antibody) amongst patients with neuromyelitis optica (nmo) and its spectrum disorders (nmosd) and the differences between the seropositive and seronegative groups. |
2014-12-30 |
2023-08-13 |
Not clear |
| Julien Ratelade, A S Verkma. Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica. Molecular immunology. vol 62. issue 1. 2014-12-29. PMID:24980869. |
neuromyelitis optica (nmo) is an inflammatory demyelinating disease of the central nervous system in which anti-aquaporin-4 (aqp4) autoantibodies (aqp4-igg) cause damage to astrocytes by complement-dependent cytotoxicity (cdc). |
2014-12-29 |
2023-08-13 |
mouse |
| Giulia Longoni, Brenda Banwell, Massimo Filippi, E Ann Ye. Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children. Neurology(R) neuroimmunology & neuroinflammation. vol 1. issue 4. 2014-12-18. PMID:25520954. |
no established therapeutic protocol has been proposed to date for childhood-onset neuromyelitis optica (nmo) spectrum disorders (nmosds). |
2014-12-18 |
2023-08-13 |
Not clear |
| Rabia Malik, Aaron Lewis, Bruce A C Cree, Julien Ratelade, Andrea Rossi, Alan S Verkman, Andrew W Bollen, Jeffrey W Ralp. Transient hyperckemia in the setting of neuromyelitis optica (NMO). Muscle & nerve. vol 50. issue 5. 2014-12-17. PMID:24862586. |
transient hyperckemia in the setting of neuromyelitis optica (nmo). |
2014-12-17 |
2023-08-13 |
Not clear |
| Rabia Malik, Aaron Lewis, Bruce A C Cree, Julien Ratelade, Andrea Rossi, Alan S Verkman, Andrew W Bollen, Jeffrey W Ralp. Transient hyperckemia in the setting of neuromyelitis optica (NMO). Muscle & nerve. vol 50. issue 5. 2014-12-17. PMID:24862586. |
neuromyelitis optica (nmo) is characterized by inflammatory demyelinating lesions of the spinal cord and optic nerves from an autoimmune response against water channel aquaporin-4 (aqp4). |
2014-12-17 |
2023-08-13 |
Not clear |
| Ismael Sánchez Gomar, María Díaz Sánchez, Antonio José Uclés Sánchez, José Luis Casado Chocán, Reposo Ramírez-Lorca, Ana Serna, Javier Villadiego, Juan José Toledo-Aral, Miriam Echevarrí. An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab. BMC neurology. vol 14. 2014-12-09. PMID:24980919. |
cell-based assays for neuromyelitis optica (nmo) diagnosis are the most sensitive and specific methods to detect anti-aquaporin 4 (aqp4) antibodies in serum, but some improvements in their quantitative and specificity capacities would be desirable. |
2014-12-09 |
2023-08-13 |
Not clear |
| Benoit Aubé, Sébastien A Lévesque, Alexandre Paré, Émilie Chamma, Hania Kébir, Roser Gorina, Marc-André Lécuyer, Jorge I Alvarez, Yves De Koninck, Britta Engelhardt, Alexandre Prat, Daniel Côté, Steve Lacroi. Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases. Journal of immunology (Baltimore, Md. : 1950). vol 193. issue 5. 2014-12-09. PMID:25049355. |
disruption of the blood-brain and blood-spinal cord barriers (bbb and bscb, respectively) and immune cell infiltration are early pathophysiological hallmarks of multiple sclerosis (ms), its animal model experimental autoimmune encephalomyelitis (eae), and neuromyelitis optica (nmo). |
2014-12-09 |
2023-08-13 |
mouse |
| Yunyun Duan, Yaou Liu, Peipeng Liang, Xiuqin Jia, Jing Ye, Huiqing Dong, Kuncheng L. White matter atrophy in brain of neuromyelitis optica: a voxel-based morphometry study. Acta radiologica (Stockholm, Sweden : 1987). vol 55. issue 5. 2014-12-08. PMID:23966367. |
recent studies have shown that tissue damage in neuromyelitis optica (nmo) is not limited to the spinal cord and optic nerve but can also appear in the brain. |
2014-12-08 |
2023-08-12 |
Not clear |
| Vincent Bryan Salvador, Sharmaine Habib, Alanna Nattis, Susan Sanelli-Russo, Vincent Rizz. Finding the missing link in neuromyelitis optica presenting with recurrent transverse myelitis flares. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 21. issue 5. 2014-12-08. PMID:24231565. |
neuromyelitis optica (nmo) is a distinct clinical entity from multiple sclerosis with its own clinical, laboratory and pathological characteristics. |
2014-12-08 |
2023-08-12 |
Not clear |